Tissue Regenix products, which are produced from human or animal tissues, have an acellular architectural structure that is comparable to human tissue, and are therefore not perceived as foreign bodies by the host tissue. This lack of rejection allows the Tissue Regenix products to work by supporting fibroblast and smooth muscle cell infiltration, re-endothelialisation and revascularisation, so that it gradually becomes incorporated into the surrounding tissue, repairing, replacing or providing strength and support to the tissue defect.

No. Tissue Regenix Products are not allergenic or immunogenic. This is due in part to the fact that the collagen has an architectural structure very similar to human tissue. The Tissue Regenix tissue processing technology removes the cellular material whilst maintaining the essential extracellular matrix proteins, rendering it acellular and therefore non-allergenic or immunogenic.

The principle of using biological materials instead of synthetic materials has long been accepted by surgeons as a method of avoiding potential foreign body reactions to the implants and reducing infection risk. Acellular biological materials in particular also have improved biocompatibility, ability to support in-growth of cells and blood vessels, and minimal or no immunogenicity, all of which are features displayed by Tissue Regenix products.

Tissue Regenix products are provided as non-viable tissues due to the removal of the cellular components using a patented decellularisation process

Yes. All Tissue Regenix products have been sterilised by a validated biocompatible liquid chemical sterilant procedure and should not be resterilised, exposed to gamma irradiation, ethylene oxide, steam or chemical fixatives.